News
EBR to Raise A$150m via Fully Underwritten Capital Raising
Listcorp carries an ASX announcement in which EBR Systems flags a fully underwritten capital raising; the page shows only the headline, with no body text or further detail.
Startup · $30m raised
EBR Systems
Developer of a left ventricular cardiac resynchronisation device
Silicon Valley, OS
Funding history
-
IPO
-
Unnamed stage : $30,000,000+
Investors
Every investor coverage indicates participated in a round EBR Systems raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon Capital | Unnamed stage | - |
| HESTA | Unnamed stage | - |
| Hostplus | Unnamed stage | - |
| M.H. Carnegie & Co | Unnamed stage | - |
| TelstraSuper | Unnamed stage | - |
On a portfolio page
Investors whose own portfolio pages list EBR Systems, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon BioCatalyst | its portfolio page ↗ |
Who bought EBR Systems
The transaction that ended EBR Systems's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| - | IPO | Nov 2021 | $110m | Brandon BioCatalyst, Brandon Capital |
What EBR Systems bought
Companies EBR Systems acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
People
| Name | Role | Sources |
|---|---|---|
| John McCutcheon | President and CEO | Wholesale Investor, Brandon Capital (17 Apr 2025), Brandon BioCatalyst, Brandon Capital (22 May 2023) |
Coverage
Stories naming EBR Systems. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Funding announcement
Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close totalling over A$430 m
Brandon Capital has completed a A$439 million final close for its sixth life sciences fund, bringing the National Reconstruction Fund Corporation and WA Government in alongside backers such as HESTA, Hostplus, CSL and QIC.
News
World-First FDA Approval for EBR Systems' Leadless Cardiac Device Opens US$3.6bn Market
Cardiac device maker EBR Systems has won US regulator clearance for its leadless heart-failure therapy, clearing the way for staged commercial release later in 2025 and broader distribution in 2026.
News
FDA Approves WiSE® System, World's First and Only Leadless Left Ventricular Endocardial Pacing (LVEP) Device for CRT
EBR Systems has won US regulatory approval for its WiSE implant, the first leadless device for a form of cardiac resynchronization therapy, which the CEO frames as the end of a 22-year development phase.
Unnamed stage
$30m+
EBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation
Cardiac pacing company EBR Systems says its SOLVE-CRT trial hit its safety and efficacy goals early, keeping a 2024 US approval bid on course; the article also recalls its 2021 ASX listing.
6 deals
Brandon Capital news
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com